With a market capitalization (market cap) of $4.05B — a measure of how much the company is worth — BillionToOne, Inc. is the 1580th most valuable company in Healthcare as of August 18, 2026. Shares trade at $87.99, down +6.30% on the day.
of 2,587
price ÷ annual EPS
FY 2025
FY 2025
FY 2025
FY 2025
FY 2025
FY 2025
FY 2025
FY 2025
FY 2025
FY 2025
FY 2025
FY 2025
FY 2025
FY 2025
FY 2025
FY 2025
FY 2025
BillionToOne, Inc. is a specialized diagnostics company that innovates by precisely quantifying biological data to create advanced molecular diagnostic solutions. Central to their operations is a cutting-edge molecular counting platform, meticulously engineered to identify and measure individual DNA molecules, thereby significantly enhancing the precision of disease detection. Their product portfolio includes: UNITY Complete: A non-invasive prenatal screen that assesses a fetus's risk for aneuploidies, recessive genetic conditions, and fetal antigens, all from a simple maternal blood sample. Northstar Select: A liquid biopsy test designed to pinpoint specific mutations present in tumors, encompassing deletions, insertions, and point mutations. Northstar Response: A diagnostic tool that enables continuous tracking of cancer progression through detailed methylation assessment. Established in 2016, BillionToOne, Inc. conducts its operations from its headquarters located in Menlo Park, California.
Visit websiteAs of August 18, 2026, BillionToOne, Inc. (BLLN) is worth $4.05B — this is its market capitalization, the total value of all its outstanding shares.
BillionToOne, Inc.’s market cap is $4.05B, which ranks it #1580 among the most valuable companies in the Healthcare sector tracked on MarketCapLens.
BillionToOne, Inc. (BLLN) shares trade at $87.99, down 6.30% on the day, as of August 18, 2026.
BillionToOne, Inc. trades at a price-to-earnings (P/E) ratio of 1381.3, based on its latest share price and annual earnings per share.
Fundamentals are annual. Figures labeled with their fiscal year.
FY 2025